Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Canaccord Genuity Group
Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity Group in a research note issued on Tuesday,Benzinga reports. They presently have a $90.00 price target on the stock. A number of other research analysts have also recently commented on NTLA. The Goldman Sachs Group reduced […]
More Stories
SigmaTron International (NASDAQ:SGMA) Releases Quarterly Earnings Results
SigmaTron International (NASDAQ:SGMA – Get Free Report) released its quarterly earnings results on Friday. The technology company reported ($1.55) earnings...
Sudan’s El Fasher siege: UN humanitarians killed as refugee crisis intensifies
The ongoing conflict in Sudan - particularly around besieged El Fasher – and a growing refugee crisis on the South...
Severin Hacker Sells 10,000 Shares of Duolingo, Inc. (NASDAQ:DUOL) Stock
Duolingo, Inc. (NASDAQ:DUOL – Get Free Report) insider Severin Hacker sold 10,000 shares of the business’s stock in a transaction...
Royal Helium (CVE:RHC) Shares Down 16.7% – Here’s What Happened
Royal Helium Ltd. (CVE:RHC – Get Free Report) fell 16.7% during mid-day trading on Friday . The company traded as...
Boston Beer (NYSE:SAM) Issues FY 2024 Earnings Guidance
Boston Beer (NYSE:SAM – Get Free Report) updated its FY 2024 earnings guidance on Friday. The company provided EPS guidance...
SharkNinja (NYSE:SN) Shares Down 4.7% – What’s Next?
SharkNinja, Inc. (NYSE:SN – Get Free Report) fell 4.7% during mid-day trading on Wednesday . The company traded as low...